Twist Bioscience Corporat... (TWST)
Twist Bioscience Statistics
Share Statistics
Twist Bioscience has 59.65M shares outstanding. The number of shares has increased by 2.45% in one year.
Shares Outstanding | 59.65M |
Shares Change (YoY) | 2.45% |
Shares Change (QoQ) | 0.5% |
Owned by Institutions (%) | 99.99% |
Shares Floating | 56.37M |
Failed to Deliver (FTD) Shares | 7.54K |
FTD / Avg. Volume | 0.65% |
Short Selling Information
The latest short interest is 9.59M, so 16.1% of the outstanding shares have been sold short.
Short Interest | 9.59M |
Short % of Shares Out | 16.1% |
Short % of Float | 18.2% |
Short Ratio (days to cover) | 11.25 |
Valuation Ratios
The PE ratio is -12.56 and the forward PE ratio is -24.54. Twist Bioscience's PEG ratio is 0.
PE Ratio | -12.56 |
Forward PE | -24.54 |
PS Ratio | 8.38 |
Forward PS | 3.1 |
PB Ratio | 5.55 |
P/FCF Ratio | -37.89 |
PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Twist Bioscience.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.88, with a Debt / Equity ratio of 0.18.
Current Ratio | 4.88 |
Quick Ratio | 4.54 |
Debt / Equity | 0.18 |
Debt / EBITDA | -0.48 |
Debt / FCF | -1.23 |
Interest Coverage | -7614.86 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $339.08K |
Profits Per Employee | $-226.14K |
Employee Count | 923 |
Asset Turnover | 0.51 |
Inventory Turnover | 7.46 |
Taxes
Income Tax | 560K |
Effective Tax Rate | -0.27% |
Stock Price Statistics
The stock price has increased by 29.8% in the last 52 weeks. The beta is 2.34, so Twist Bioscience's price volatility has been higher than the market average.
Beta | 2.34 |
52-Week Price Change | 29.8% |
50-Day Moving Average | 41.39 |
200-Day Moving Average | 45.42 |
Relative Strength Index (RSI) | 43.01 |
Average Volume (20 Days) | 1.16M |
Income Statement
In the last 12 months, Twist Bioscience had revenue of 312.97M and earned -208.73M in profits. Earnings per share was -3.6.
Revenue | 312.97M |
Gross Profit | 133.35M |
Operating Income | -220.83M |
Net Income | -208.73M |
EBITDA | -176.71M |
EBIT | -208.14M |
Earnings Per Share (EPS) | -3.6 |
Balance Sheet
The company has 226.32M in cash and 85.03M in debt, giving a net cash position of 141.29M.
Cash & Cash Equivalents | 226.32M |
Total Debt | 85.03M |
Net Cash | 141.29M |
Retained Earnings | -1.24B |
Total Assets | 608.58M |
Working Capital | 275.66M |
Cash Flow
In the last 12 months, operating cash flow was -64.09M and capital expenditures -5.08M, giving a free cash flow of -69.17M.
Operating Cash Flow | -64.09M |
Capital Expenditures | -5.08M |
Free Cash Flow | -69.17M |
FCF Per Share | -1.19 |
Margins
Gross margin is 42.61%, with operating and profit margins of -70.56% and -66.69%.
Gross Margin | 42.61% |
Operating Margin | -70.56% |
Pretax Margin | -66.51% |
Profit Margin | -66.69% |
EBITDA Margin | -56.46% |
EBIT Margin | -70.56% |
FCF Margin | -22.1% |
Dividends & Yields
TWST does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for TWST is $56, which is 52.1% higher than the current price. The consensus rating is "Buy".
Price Target | $56 |
Price Target Difference | 52.1% |
Analyst Consensus | Buy |
Analyst Count | 9 |
Scores
Altman Z-Score | 6.43 |
Piotroski F-Score | 3 |